Tailwinds' Take: this deal demonstrates the effectiveness of FBIO's business model. They are accumulating a plethora of interesting drugs under their umbrella.  NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) today announced that Baergic...
SAN JOSE, Calif., Dec. 23, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system in the fight against cancer, today announced that its chief executive officer, Dr. Amit Kumar, will present...
The name Tailwinds does not come, as is commonly assumed by many readers, from my love of sailing. An understandable assumption, based on our sailboat logo, but the reality is I get seasick the second I go below deck...
Tailwinds' Take: we continue to believe that video gaming is going to be a huge market for WiSA products in the near future. SAN JOSE, Calif.--(BUSINESS WIRE)-- WiSA® LLC, the Wireless Speaker Audio Association, founded by Summit Wireless Technologies, Inc. (NASDAQ: WISA), today...
IRVINE, California, December 20, 2019 – Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that an abstract entitled Results of First-in-Human Implantation of a Prosthetic Venous Valve...
Please click on the link below to see the complete transcript from Anixa's Investor Update conference call of December 17th, 2019. ANIXA_12172019 transcript
When I first got involved with Patriot One (PAT), the story was very simple. They had a product, the Cognitive Magnetic Radar (CMR), that was going to be capable of screening for concealed weapons. Similar to a metal detector,...
New York - (NewMediaWire) - December 17, 2019 - PeerStream, Inc. (“PeerStream,” the “Company,” “we,” “our” or “us”) (OTCQB: PEER), a communications software innovator developing enhanced security and privacy solutions for multimedia communication and data transmission, today announced that...
Tailwinds' Take: this is a very positive step for this platform. Next steps here are to start a Phase IIa open-label trial next summer, with expected results about 12 months after dosing patients. Herceptin is a relatively uncrowded space...
Tailwinds' Take: "significantly increasing our outreach pool". That about sums up this press release. Catasys is likely to exceed 2020 guidance and continue expanding rapidly beyond then. Santa Monica, CA - December 17, 2019 -Catasys, Inc. (NASDAQ: CATS) ("Catasys" or...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.